A leaner, purpose-built July edition trades the record-breaking scale of last year’s co-located show for sharper, deal-driven engagement across processing, packaging, automation and cleanroom technology, Rashmi Kumari of Neo Science Hub, reports.
The 12th edition of the Pharma Pro&Pack Expo drew its three-day run to a close here in Hyderabad on Saturday evening, having reasserted the show’s core proposition: that the machinery, packaging lines and automation systems shaping India’s pharmaceutical output are best evaluated where a large share of that output is actually made. Organised by Messe Muenchen India, the exhibition occupied the HITEX halls from 9 to 11 July, positioning itself, in the organiser’s own framing, as South India’s premier platform for pharma processing and packaging technology.
What distinguished this edition was as much a matter of structure as of scale. In September 2025, the show ran co-located with analytica Lab India across seven halls and roughly 50,000 square metres, a combined event that reported more than 650 exhibitors and 32,149 visitors under the banner “Epicentre of Progress.” The 2026 pharma exhibition instead stood on its own in July — analytica Lab India is separately slated to return to the same venue in September — and its reported footprint, of the order of 30,000 square metres, 350-plus participating brands and upward of 10,000 products on display, reflects that decoupling rather than any loss of momentum. The trade-off is deliberate: a tighter, manufacturing-focused floor in place of a sprawling science-and-industry convergence.
On the ground, that focus was visible in the composition of the aisles. Processing and packaging machinery dominated, flanked by a Software Pavilion, an International Pavilion and clusters of utility, cleanroom and analytical suppliers. Organiser communications reported visitor turnout in the range of 25,000 professionals and buyers over the three days — procurement heads, plant and engineering leads, quality and regulatory specialists, and R&D formulators — the mix that converts a trade fair from a showcase into a marketplace. Exhibitors across both days reported dense booth traffic and, more tellingly, the kind of extended technical conversations that precede capital-equipment decisions rather than casual footfall.
Why the venue matters
Hyderabad’s selection is not incidental branding. The Telangana–Andhra Pradesh corridor accounts for a substantial share of India’s bulk-drug and active-pharmaceutical-ingredient production, and HITEX sits within reach of the Jeedimetla, Gachibowli and Patancheru manufacturing clusters via the Outer Ring Road. That geography let international technology suppliers meet the decision-makers of the generics and formulation industry face to face — a proximity that repeatedly surfaced in exhibitor commentary as the reason for participating in a southern, rather than western-Indian, show.
The commercial backdrop lent urgency to the proceedings. The Indian pharmaceutical market is projected by the organiser and widely cited industry sources to expand from roughly USD 41.7 billion toward USD 130 billion by 2030, a trajectory that depends heavily on the sector’s ability to modernise plants, tighten contamination control and satisfy increasingly demanding export regulators. Against that, an exhibition devoted to the hardware and software of compliant, efficient manufacturing reads less as a marketing event and more as a procurement instrument.
The outcome, in balance
Judged on its own terms, the 12th edition delivered a coherent, sharply-scoped event rather than a headline-scale spectacle. The absence of a co-located analytical fair narrowed the visitor base but arguably improved its quality, concentrating the audience around manufacturing and packaging rather than laboratory science. The show’s recurring motifs — automation replacing manual handling, closed and contained processing, digital traceability, and sustainable packaging — were consistent across the conference programme, the exhibitor floor and the informal conversations in the networking zones, which is itself a marker of a well-curated event.
A candid caveat is owed to readers: at the time of filing, Messe Muenchen India had not released an audited post-event report for the standalone July edition, so the participation figures cited here are the show’s reported and promoted numbers rather than independently verified totals. What can be stated without qualification is that the exhibition reinforced Hyderabad’s standing as the operational heart of Indian pharmaceutical manufacturing, and that the technologies it foregrounded map closely onto the regulatory and competitive pressures the industry now faces.
